Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial

Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Juszczyk, Ewelina, Kisło, Kamil, Żero, Paweł, Tratkiewicz, Ewa, Wieczorek, Maciej, Paszkowska, Jadwiga, Banach, Grzegorz, Wiater, Marcela, Hoc, Dagmara, Garbacz, Grzegorz, Sczodrok, Jaroslaw, Danielak, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227174/
https://www.ncbi.nlm.nih.gov/pubmed/34071286
http://dx.doi.org/10.3390/pharmaceutics13060804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227174/
https://www.ncbi.nlm.nih.gov/pubmed/34071286
http://dx.doi.org/10.3390/pharmaceutics13060804

Ejemplares similares